Industry Applauds US FDA Plans For Novel Excipients Review Pathway, But Urges Refinement
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.